Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia
The Phosphodiesterase Inhibitor Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
Sponsor: Sadat City University
Listed as NCT04094207, this PHASE1/PHASE2 trial focuses on Schizophrenia and remains completed. Sponsored by Sadat City University, it has been updated 12 times since 2019, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2019 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sadat City University
For direct contact, visit the study record on ClinicalTrials.gov .